RBC Capital analyst Keith Mackey reiterates Shawcor (TSX:SCL) with a Outperform and maintains C$15 price target.
Where Stoke Therapeutics Stands With Analysts
Stoke Therapeutics (NASDAQ:STOK) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…